drugset / Trial / NCT04294277
Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery
Phase 2
Terminated
2 enrolled
European Association of Urology Research Foundation
AMS Advanced Medical Services GmbH · collabHigh Research s.r.l. · collabIncyte Biosciences International Sàrl · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to demonstrate the benefit of Pemigatinib, a drug that has indicated promising effects for relapse free survival in molecularly-selected, high-risk patients with urothelial carcinoma (UC) who have received radical surgery. Patients will receive Pemigatinib at a once-daily dose on a continuous schedule, continued until 12 months.
Timeline
- Start
- 2020-07-13
- Primary completion
- 2021-11-15
- Completion
- 2022-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemigatinib | Small molecule | 13.5 mg | Oral |